Ipopema Securities analysts, in a report dated December 6, 2021, started to issue recommendation “buy” for biotechnological company PolTREG S.A., evaluating one share of the company at PLN 155.

“We estimate PolTREG using the rNPV method, from which we have received a price at PLN 155 per share. The Treg 2.0 project and cooperation with AZTherapies (the cooperation agreement already signed after the IPO) have the potential to increase our pricing, since the forecasts take into account some costs associated with these projects, but we do not take into account their commercialisation”, analysts wrote in the report.